Trial record 17 of 65 for:
cholangiocarcinoma | Open Studies
A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection
This study is currently recruiting participants.
Verified April 2012 by National Cancer Center, Korea
Sponsor:
National Cancer Center, Korea
Collaborator:
Dong-A Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Sang Myung Woo, National Cancer Center, Korea
ClinicalTrials.gov Identifier:
NCT01043172
First received: January 5, 2010
Last updated: April 25, 2012
Last verified: April 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The investigators propose to evaluate efficacy and safety of gemcitabine in the adjuvant treatment of cholangiocarcinoma after potentially curative treatment with surgical resection.
| Condition | Intervention | Phase |
|---|---|---|
|
Cholangiocarcinoma |
Drug: Gemcitabine |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase II Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection |
Resource links provided by NLM:
Further study details as provided by National Cancer Center, Korea:
Primary Outcome Measures:
- Primary objective: To investigate the proportion of patients who are recurrence-free for 2 years [ Time Frame: Jan 2010 - Jan 2014 (24 month enrollment, 24 month follow-up) ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Time to Recurrence (TTR) Recurrence Free Survival (RFS) QOL [ Time Frame: Jan 2010 - Jan 2014 (24 month enrollment, 24 month follow-up) ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 72 |
| Study Start Date: | January 2010 |
| Estimated Study Completion Date: | December 2015 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Gemcitabine |
Drug: Gemcitabine
Gemcitabine : 1000 mg/m2/day D1,8,15 Repeated every 4 weeks 6 cycles
|
Detailed Description:
Cholangiocarcinoma is a highly fatal disease with poor prognosis. While Cholangiocarcinoma is generally rare in Western countries, it is more common in Korea, with an estimate of 3500 cases diagnosed annually. Currently, surgical resection remains the only potentially curative treatment, but many patients develop recurrence. Thus, effective postoperative adjuvant therapy is required to prolong survival in patients with cholangiocarcinoma. However, no standard postoperative treatment has been established yet.
Among several different new anticancer drugs currently being investigated in the treatment of advanced biliary tract cancer, gemcitabine has generated particular interest. The nucleoside analogue gemcitabine has been reported to be active against advanced unresectable cholangiocarcinoma including cancer of the gallbladder, intrahepatic, and extrahepatic bile duct. So this is expected to be investigated in the adjuvant setting.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Subjects undergoing curative surgical resection for cholangiocarcinoma (including cancer of the gallbladder [except stage I], intrahepatic, and extrahepatic bile duct)
- Histological confirmation is mandatory.
- Age over 18 years old
- Performance status (ECOG scale): 0-2
- Adequate organ functions Hb ≥ 9.0 g/dl ANC: ≥ 1,500/mm3 PLT ≥ 100,000 /mm3 Liver function: Total Bilirubin ≤ 2.0 mg/dl AST / ALT / ALP ≤ 3× upper limit of normal Creatinine ≤ 1.5 ULN
- Patients should sign a written informed consent before study entry.
Exclusion Criteria:
- Tumor type other than adenocarcinoma
- Stage I gallbladder cancer
- Noncurative surgical resection including R2 resection
- Other primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin or prior malignancy treated more than 5 years ago without recurrence)
- Prior systemic therapy (for instance, cytotoxic chemotherapy or active/passive immunotherapy)
- Prior radiotherapy
- Major surgery within 4 weeks prior to study treatment except for surgical resection of cholangiocarcinoma
- Serious illness or medical conditions, as follows; congestive heart failure (NYHA class III or IV) unstable angina or myocardial infarction within the past 6 months, significant arrhythmias requiring medication and conduction abnormality such as over 2nd degree AV block uncontrolled hypertension hepatic cirrhosis(≥ Child class B) interstitial pneumonia, pulmonary adenomatosis psychiatric disorder that may interfere with and/or protocol compliance unstable diabetes mellitus uncontrolled ascites or pleural effusion active infection
- Received any investigational drug or agent/procedure, i.e. participation in another trial within 4 weeks before beginning treatment with study drug
- Pregnant or lactating woman
- Women of child bearing potential not using a contraceptive method
- Sexually active fertile men not using effective birth control during medication of study drug and up to 6 months after completion of study drug if their partners are women of child-bearing potential
- Any patients judged by the investigator to be unfit to participate in the study
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01043172
Contacts
| Contact: Sang Myung Woo, MD | 82-31-920-1612 | wsm@ncc.re.kr |
Locations
| Korea, Republic of | |
| National Cancer Center | Recruiting |
| Goyang, Gyeonggi, Korea, Republic of, 410-769 | |
| Contact: Sang Myung Woo, MD 82-31-920-1612 wsm@ncc.re.kr | |
Sponsors and Collaborators
National Cancer Center, Korea
Dong-A Pharmaceutical Co., Ltd.
Investigators
| Principal Investigator: | Woo Jin Lee, MD | National Cancer Center, Korea |
More Information
No publications provided
| Responsible Party: | Sang Myung Woo, MD, National Cancer Center, Korea |
| ClinicalTrials.gov Identifier: | NCT01043172 History of Changes |
| Other Study ID Numbers: | GATCO-1 |
| Study First Received: | January 5, 2010 |
| Last Updated: | April 25, 2012 |
| Health Authority: | Korea: Food and Drug Administration |
Additional relevant MeSH terms:
|
Cholangiocarcinoma Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Gemcitabine Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action |
Pharmacologic Actions Antineoplastic Agents Therapeutic Uses Antiviral Agents Anti-Infective Agents Enzyme Inhibitors Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Radiation-Sensitizing Agents |
ClinicalTrials.gov processed this record on May 23, 2013